Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

Drugs - 1 Mar 2026

Abdayem Pamela, Parisi Claudia, Planchard David

Abstract excerpt

The therapeutic landscape for non-small-cell lung cancer (NSCLC) harbouring epidermal growth factor (EGFR) gene mutations is undergoing significant transformation. For classical EGFR mutations such as exon 19 deletion and exon 21 L858R mutation, combination strategies in the first-line setting, based on the results of the MARIPOSA (lazertinib and amivantamab) and FLAURA 2 (platinum-based doublet chemotherapy and...

Topics

Join the communities discussing this publication.

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41619151
DOI: 10.1007/s40265-025-02276-9
PMCID: PMC12963156

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?PMID 41619151Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewSemantic proximity Read ↗

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read ↗

Targeted therapeutic options in early and metastatic NSCLC-overview.Semantic proximity Read ↗

Treatment sequences in EGFR mutant advanced NSCLC.Semantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.Semantic proximity Read ↗

Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.Semantic proximity Read ↗

Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients.Semantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.